Which injectable compounds pair most effectively with Oxymetholone 50mg in a mass-building stack?

Testosterone Enanthate and Testosterone Cypionate are the most established injectable partners for oxymetholone-based stacks because their accumulation timelines overlap directly with the oral compound's active window. Nandrolone Decanoate is a secondary option, adding connective-tissue support that complements oxymetholone's rapid volumising effect. Both combinations are documented across practitioner literature as producing synergistic mass gains superior to either compound used alone.

What is considered the classic oxymetholone stack in competitive bodybuilding?

The classic combination places Oxymetholone at 50 mg per day alongside a testosterone ester base — historically Testosterone Enanthate at 400–600 mg per week — with cycle duration anchored to the injectable's ester length. This pairing has appeared consistently in bodybuilding literature since the 1980s because it combines immediate erythropoietic output from the oral with sustained androgenic and anabolic signalling from the injectable, producing a complementary rather than redundant mechanism profile.

What factors should I evaluate before designing an Oxymetholone-based compound stack?

Before building a stack around oxymetholone, evaluate baseline liver enzyme levels (ALT and AST), haematocrit, and blood pressure, since oxymetholone contributes hepatic load and erythropoietic elevation to the combined physiological burden. Assign each compound in the stack a distinct role — oral for rapid volumisation, injectable for sustained tissue accretion — and plan aromatase inhibitor inclusion based on the oestrogenic potential of the injectable base compound selected.

How does the 50mg per tablet concentration of Magnus Pharmaceuticals Oxymetholone benefit stack planning specifically?

At 50 mg per tablet — the highest standard concentration available in this oxymetholone format group — each unit delivers the full reference stack dose in a single analytically verified tablet, removing the measurement ambiguity introduced by splitting lower-dose tablets. For stack practitioners where daily oral androgen dose is fixed by protocol, single-tablet-per-day administration ensures the injectable-to-oral ratio remains consistent across the entire cycle without adjustment.

Are the tablets in this Magnus Pharmaceuticals pack suitable for splitting within a stack protocol, or should they be taken whole?

The 50 mg tablets are pressed as uniform, film-coated units and can be split for practitioners who design stacks incorporating a reduced oxymetholone dose alongside a higher-dose injectable base. Magnus Pharmaceuticals' HPLC content uniformity verification confirms API distribution across each compressed tablet, meaning a half-tablet delivers a predictable 25 mg dose rather than a variable fraction — a requirement for stack protocols where the oral-to-injectable ratio is dose-sensitive. (2) angle_used

Original Product

Magnus Pharmaceuticals

Oxymetholone 50mg/tab 50 Tabletten by Magnus Pharmaceuticals

Name: Oxymetholone 50mg/tab 50 Tablets by Magnus Pharmaceuticals
Brand: Magnus Pharmaceuticals
SKU: ORA-OXYM-MAG-013
Price: 50.00 EUR
Availability: InStock

Magnus Pharmaceuticals Oxymetholone provides 50 mg of pharmaceutical-grade oxymetholone per tablet in a 50-tablet pack, formulated as the oral androgen anchor within structured multi-compound mass cycles where rapid volumisation and erythropoietic drive are required from day one. Each tablet delivers precise API content verified by HPLC uniformity testing, ensuring the oral-to-injectable dosing ratio planned at protocol design is maintained across every unit in the pack. Batch-level authenticity is secured through serialised hologram seals and a manufacturer-issued verification code; every lot undergoes HPLC content assay and LAL endotoxin screening before release.

€50.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Rapid erythropoietic activity elevates red blood cell count within the first two weeks, enhancing oxygen delivery to working muscle tissue across the stack.
Pronounced intracellular volumisation provides an immediate size and strength advantage at stack onset before injectable compounds reach steady-state.
50 mg per tablet — the highest standard unit concentration in this product group — delivers a full stack dose in a single verified tablet per day.
DHT-derived structure eliminates aromatisation from the oral component, allowing oestrogenic management to focus solely on the injectable partner's conversion.
HPLC-confirmed content uniformity ensures the oral-to-injectable pharmacological ratio in the stack remains predictable across every tablet in the pack.
50-tablet count aligns exactly with a four-week oral component block, covering the standard induction window of long-ester injectable stacks without surplus.
Serialised hologram and manufacturer verification code authenticate each pack, protecting stack integrity from underdosed or counterfeit product risk.

Phase	dosage	Note
Stack Induction (Weeks 1–2)	25–50 mg/day Oxymetholone + Injectable Base at full weekly dose	Begin injectable compound simultaneously; oxymetholone covers the accumulation gap while long-ester compounds build toward steady-state plasma levels.
Stack Peak (Weeks 3–4)	50 mg/day Oxymetholone + Injectable Base continued	Both compounds now active; monitor ALT/AST and haematocrit at the week-4 boundary to assess hepatic and haematopoietic load from the combined stack.
Injectable Continuation (Weeks 5–12)	Oxymetholone discontinued; Injectable Base maintained	Oral component is withdrawn after four weeks; injectable sustains anabolic output through the remainder of the cycle without oral hepatic contribution.
PCT / Cycle Exit	Per injectable ester clearance timeline	Initiate PCT based on the longest-ester injectable in the stack; oxymetholone clears within 48 hours of last dose and does not delay PCT start timing.

Key takeaways

Anchor your mass stack with Oxymetholone 50mg alongside a long-ester testosterone base.
Assign each stack compound a distinct physiological role to avoid mechanism overlap.
Pair Nandrolone Decanoate with Oxymetholone to offset volumisation-related joint stress.
Verify batch authenticity via Magnus Pharmaceuticals' serialised hologram before starting your stack.
Monitor ALT, AST, and haematocrit throughout any multi-compound stack containing oxymetholone.

Oxymetholone as a Stack Anchor: Defining Its Role in Multi-Compound Protocols

Oxymetholone, as formulated by Magnus Pharmaceuticals at 50 mg per tablet, is a 17α-alkylated DHT-derived oral androgen whose primary clinical and performance application in modern bodybuilding is as the dominant oral component within a structured multi-compound stack rather than as a standalone agent. The compound's pronounced erythropoietic drive and rapid tissue-volumising mechanism make it uniquely suited to pairing with slower-acting injectables that require time to accumulate before contributing meaningful anabolic output. Oxymetholone accelerates early-cycle nitrogen retention, which gives the entire stack a measurable head start that single-compound approaches cannot replicate at equivalent doses.

Which Injectable Partners Complement Oxymetholone Best

Oxymetholone stacks most productively with long-ester testosterone esters — Testosterone Enanthate and Testosterone Cypionate are the established clinical and practitioner references — because the ester-clearance timeline, measured in days to steady-state plasma concentration, aligns precisely with the window where oral androgen activity is highest. Compared to pairing oxymetholone with a short-ester injectable such as Testosterone Propionate, the long-ester combination produces a more sustained and sequential anabolic arc: the oral phase delivers peak tissue response in weeks one through four while the injectable transitions from accumulation to steady-state. Nandrolone Decanoate represents a second validated partner, contributing connective-tissue support and joint fluid retention that partially offsets the osmotic intracellular stress generated by rapid oxymetholone-driven volumisation.

Stack Architecture: Sequencing, Overlap, and Compound Roles

Effective stack design assigns each compound a discrete physiological role rather than layering similar mechanisms. Within an oxymetholone-anchored stack, the oral component owns erythropoiesis and rapid intracellular volumisation; the injectable base compound owns sustained androgenic signalling and lean tissue accretion; an optional aromatase inhibitor — anastrozole or letrozole, dosed according to serum oestradiol monitoring — manages the combined oestrogenic load of the injectable component. Practitioners who incorporate hepatoprotective agents such as UDCA (ursodeoxycholic acid) or TUDCA, confirmed effective by ALT/AST trajectory data in published hepatology literature, reduce the liver-enzyme burden associated with the 17α-alkylated component without altering the stack's androgenic output.

Magnus Pharmaceuticals Quality Framework for Stack Reliability

Stack planning depends on tablet-level dosing accuracy; a unit that varies in API delivery disrupts the pharmacological balance between oral and injectable components. Magnus Pharmaceuticals addresses this through a batch-release model that routes each Oxymetholone lot through HPLC-verified content uniformity testing and LAL-method endotoxin screening of the raw API before compression. Each pack carries a serialised hologram and manufacturer verification code that connects the physical product to its released certificate of analysis, enabling the end user to confirm batch identity independently before integrating the tablets into a stack protocol.

Usage

Map the full stack before beginning: identify each compound's role (oral volumiser, injectable base, ancillary), weekly dose, and injection frequency so the oxymetholone contribution is correctly positioned within the combined protocol.
Obtain pre-stack bloodwork including ALT, AST, haematocrit, serum testosterone, and lipid panel to establish individual baselines against which stack-induced changes will be measured.
Begin oxymetholone at 25–50 mg per day on day one of the cycle, taken with a light meal to reduce gastric irritation; administer the injectable base compound on its scheduled injection day in the same first week.
Authenticate each blister strip using the Magnus Pharmaceuticals hologram and verification code before breaking the seal, confirming product identity before it enters your stack protocol.
At the four-week mark, cease oxymetholone administration and continue the injectable base compound only; schedule a repeat ALT/AST blood draw within five to seven days of stopping the oral component to confirm hepatic enzyme recovery.
At injectable cycle end, initiate PCT according to the ester-specific clearance timeline of your injectable partner — Testosterone Enanthate typically requires a 14-day gap before SERMs are introduced — and do not extend oxymetholone use into the PCT window.

Warnings

Contraindications: Oxymetholone is contraindicated in individuals with pre-existing hepatic impairment, elevated haematocrit above 50%, diagnosed cardiovascular disease, active or suspected hormone-sensitive malignancy, and in women who are pregnant or breastfeeding. Adolescents and individuals under 21 should not use this compound.

Side Effects: Stacking oxymetholone with injectable androgens compounds the individual side-effect profiles of each compound. Expected effects include significant intracellular water retention, elevation of serum haematocrit and blood viscosity, suppression of endogenous testosterone production, HDL cholesterol reduction, potential elevation of blood pressure, and hepatic enzyme elevation driven by the 17α-alkylated structure of the oral component.

Monitoring: Blood panels including ALT, AST, total bilirubin, haematocrit, lipid profile, and blood pressure should be assessed at stack entry and again at the two-week and four-week marks during oxymetholone co-administration. Any ALT or AST reading exceeding three times the upper limit of the reference range should prompt immediate dose reassessment or cessation of the oral compound.

PCT: Endogenous testosterone suppression is driven by the combined androgenic load of the entire stack. Post-cycle therapy using a SERM — typically tamoxifen or clomiphene — should be initiated once the longest-ester injectable has cleared sufficiently; oxymetholone's short clearance window does not independently delay PCT initiation.

Frequently asked questions

Which injectable compounds pair most effectively with Oxymetholone 50mg in a mass-building stack?: Testosterone Enanthate and Testosterone Cypionate are the most established injectable partners for oxymetholone-based stacks because their accumulation timelines overlap directly with the oral compound's active window. Nandrolone Decanoate is a secondary option, adding connective-tissue support that complements oxymetholone's rapid volumising effect. Both combinations are documented across practitioner literature as producing synergistic mass gains superior to either compound used alone.
What is considered the classic oxymetholone stack in competitive bodybuilding?: The classic combination places Oxymetholone at 50 mg per day alongside a testosterone ester base — historically Testosterone Enanthate at 400–600 mg per week — with cycle duration anchored to the injectable's ester length. This pairing has appeared consistently in bodybuilding literature since the 1980s because it combines immediate erythropoietic output from the oral with sustained androgenic and anabolic signalling from the injectable, producing a complementary rather than redundant mechanism profile.
What factors should I evaluate before designing an Oxymetholone-based compound stack?: Before building a stack around oxymetholone, evaluate baseline liver enzyme levels (ALT and AST), haematocrit, and blood pressure, since oxymetholone contributes hepatic load and erythropoietic elevation to the combined physiological burden. Assign each compound in the stack a distinct role — oral for rapid volumisation, injectable for sustained tissue accretion — and plan aromatase inhibitor inclusion based on the oestrogenic potential of the injectable base compound selected.
How does the 50mg per tablet concentration of Magnus Pharmaceuticals Oxymetholone benefit stack planning specifically?: At 50 mg per tablet — the highest standard concentration available in this oxymetholone format group — each unit delivers the full reference stack dose in a single analytically verified tablet, removing the measurement ambiguity introduced by splitting lower-dose tablets. For stack practitioners where daily oral androgen dose is fixed by protocol, single-tablet-per-day administration ensures the injectable-to-oral ratio remains consistent across the entire cycle without adjustment.
Are the tablets in this Magnus Pharmaceuticals pack suitable for splitting within a stack protocol, or should they be taken whole?: The 50 mg tablets are pressed as uniform, film-coated units and can be split for practitioners who design stacks incorporating a reduced oxymetholone dose alongside a higher-dose injectable base. Magnus Pharmaceuticals' HPLC content uniformity verification confirms API distribution across each compressed tablet, meaning a half-tablet delivers a predictable 25 mg dose rather than a variable fraction — a requirement for stack protocols where the oral-to-injectable ratio is dose-sensitive. (2) angle_used

Manufacturer

Authenticity verification and supply-chain transparency are the two manufacturing dimensions that Magnus Pharmaceuticals has architectured most visibly into the Oxymetholone 50mg tablet line. Each production lot is assigned a serialised batch code that is physically embedded in the hologram seal applied to every blister pack; this code connects the physical unit to a manufacturer-issued certificate of analysis that covers HPLC-determined API content, tablet uniformity data, and LAL endotoxin screening results on the raw oxymetholone API before compression. The verification mechanism is designed to be end-user accessible: the code can be cross-referenced through Magnus Pharmaceuticals' product authentication system, allowing a practitioner to confirm batch identity and release status independently — without relying solely on distributor representation. This approach to traceability is particularly relevant for stack-based protocols, where API accuracy in the oral component directly determines whether the planned compound ratio between tablet and injectable is pharmacologically achieved.

Product details

Brand	Magnus Pharmaceuticals
Active ingredient	oxymetholone
Also known as	Anadrol, Anapolon, Oxymetholone, Oxymetholonee, Magnus Pharmaceuticals Anadrol
Strength	50 mg
Form	Tabletten
Pack size	50 pieces
Item number	ORA-OXYM-MAG-013

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Anapolon 50mg/tab 20 Tablets by Abdi Ibrahim

Lab Tested

Anapolon 50mg/tab 20 Tabletten by Abdi Ibrahim

Anapolon (Oxymetholone) by Abdi Ibrahim is a 17α-alkylated dihydrotestosterone-derived oral anabolic steroid, dosed at 50 mg per tablet across 20 tablets, whose primary pharmacological identity is defined by its high-affinity interaction with androgen receptors combined with a marked capacity to stimulate erythropoietin production. As a DHT-lineage compound, Oxymetholone cannot be aromatised directly yet drives powerful anabolic signalling through androgen receptor activation and progesterone receptor cross-reactivity. Quality is enforced at every production stage: HPLC purity verification, LAL endotoxin testing, and GMP-certified manufacturing conditions underpin every blister pack released by Abdi Ibrahim.

€20.00

Anapolon 50mg/tab 60 Tablets by Balkan Pharmaceuticals

HPLC Verified

Anapolon 50mg/tab 60 Tabletten by Balkan Pharmaceuticals

Anapolon by Balkan Pharmaceuticals is an oral anabolic tablet delivering 50 mg of Oxymetholone per dose, clinically characterised by a plasma half-life of approximately 8–9 hours that governs its twice-daily administration schedule. The pharmacokinetic profile allows predictable plasma-level maintenance without the accumulation spikes associated with longer-half-life oral androgens, making timed dosing a core performance variable. Batch-release integrity is enforced through post-compression HPLC quantification and LAL endotoxin screening — each of the 60 tablets verified against declared potency before dispatch.

€48.00

Pro-Anadrol 50mg/tab 50 Tablets by Beligas Pharmaceuticals

Pharma Grade

Pro-Anadrol 50mg/tab 50 Tabletten by Beligas Pharmaceuticals

Pro-Anadrol delivers Oxymetholone at 50 mg per tablet across a 50-tablet pack — an oral androgen whose systemic bioavailability is shaped entirely by first-pass hepatic metabolism, distinguishing its absorption profile sharply from any injectable androgenic compound. Because the molecule must survive gastrointestinal transit and initial liver processing before entering systemic circulation, oral Oxymetholone achieves estimated bioavailability in the 56–70 % range, a figure that injectable routes bypass entirely by delivering the active substance directly into the bloodstream. Batch-level potency is confirmed at Beligas Pharmaceuticals through HPLC quantification against certified pharmacopoeial reference standards, with LAL endotoxin screening applied to raw excipient inputs before tableting proceeds.

€60.00

OxyTrex 25mg/tab 100 Tablets by Concentrex Labs

Purity Tested

OxyTrex 25mg/tab 100 Tabletten by Concentrex Labs

OxyTrex by Concentrex Labs delivers Oxymetholone at 25 mg per tablet across 100 tablets, formulated specifically for athletes studying how this potent oral androgen interacts with insulin sensitivity and glucose partitioning during hypertrophic loading phases. Oxymetholone's documented capacity to alter nutrient uptake dynamics — shifting glucose disposal toward skeletal muscle — makes it a subject of sustained interest in metabolic-context bodybuilding literature. Purity Tested at the finished-tablet stage via HPLC quantification; each released lot carries a batch record confirming active-content compliance against a certified reference standard.

€60.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00